Egle Therapeutics Identifies First Novel Regulatory T-cell Targets in Research Alliance with Takeda
26.11.2020 13:30:00 EET | Business Wire | Press release
Egle Therapeutics SAS (Egle), an emerging biotechnology company focused on developing first-in class immunotherapies targeting immune suppressor regulatory T-cells (Tregs) for oncology and autoimmune diseases, today announces that it has achieved the first milestone in its strategic research alliance with Takeda Pharmaceutical Company Limited (“Takeda”). In the course of the strategic research alliance that was announced in June 2020, Egle will validate novel tumor-infiltrating regulatory T-cell (Treg) targets against which Takeda will develop potential therapies.
Egle has leveraged its unique bioinformatic and translational capabilities to successfully identify targets that will now be pursued under the terms of the alliance. Upon achievement of the target identification, Egle will receive an R&D milestone payment and investment from Takeda.
Luc Boblet, CEO of Egle, commented “Reaching this first technical milestone marks our positive progress towards our joint goal with Takeda, of creating the next generation of differentiated immunotherapies against Tregs, and provides strong validation of the work being done at Egle. We look forward to continuing our productive alliance with Takeda while pushing further our internal programs through the equity component of the alliance.”
“We have made great progress in our collaboration with Egle and are thrilled with the speed of which we identified our first novel Treg targets,” said Loïc Vincent, Head, Oncology Drug Discovery Unit at Takeda. “We hope to build upon this momentum in the next phase of our partnership to enable and ultimately deliver new immuno-oncology therapeutic options.”
About Egle Therapeutics
Established in early 2020, as a spin-out of Institut Curie by Luc Boblet, serial biotech entrepreneur (former co-founder and CEO of PathoQuest, and former co-founder and CEO of H-Immune sold to HifiBio Therapeutics) and Dr Eliane Piaggio, PhD, renowned immunologist in the Treg / IL-2 field (INSERM Research Director, Head of the Translational Immunotherapy Team – TransImm – at Institut Curie), Egle Therapeutics is developing first-in-class immunotherapies targeting immune suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases.
The key element of Egle’s core approach is the leveraging of its translational-based target discovery engine to unveil novel therapeutic Treg targets and vectorize computationally designed resurfaced cytokines acting as antagonists or as selective Treg-agonists. Egle’s flagship program pioneers dis-engagement of tumor-infiltrating Tregs through a proprietary series of IL-2 variants featuring a unique antagonism mechanism of action.
To find out more about Egle Therapeutics, please visit www.egle-tx.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201126005532/en/
Contact information
Luc Boblet
Chief Executive Officer
Email: lboblet@egle-tx.com
Images
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Jeito Capital Hits Record $1.2 Billion (€1 Billion) 1 Close for Jeito II Fund to Drive Breakthrough Therapeutic Innovation for Patients8.4.2026 09:15:00 EEST | Press release
Jeito Capital (“Jeito”), a global independent private equity fund dedicated to Biopharma, today announces the final closing of its second fund Jeito II, exceeding its target at $1.2billion (above €1billion)1,2, and marking a new major milestone for European Biopharma investment. With this new fund, Jeito has now tripled its assets under management to €1.6 billion, following the closing in 2021 of fund Jeito I at $630 million (€534 million) and reinforces its position as a leading fully independent European Biopharma investor. Jeito II will continue the strategy established with Jeito I: selectively identifying and backing 15 to 20 of the most promising clinical stage Biopharma companies, primarily in Europe, developing breakthrough therapies for severe diseases with high unmet medical needs and accelerating the development path and future market access. This fundraising allows Jeito to increase the average size of future investments in portfolio companies up to €150 million, thus drivi
Croma-Pharma Acquires Synocrom™ and Returns to Orthopaedics8.4.2026 08:00:00 EEST | Press release
Croma-Pharma is returning to the orthopaedics market with the reacquisition of Synocrom™, a hyaluronic acid product for the treatment of knee osteoarthritis. A strategic return built on proven heritage With the reacquisition of Synocrom™, Croma-Pharma is re-entering orthopaedics and further broadening its portfolio in a field with strong historical roots for the company. Until 2014, Croma was active in orthopaedics, with Synocrom™ serving as a key pillar of its offering. Synocrom™ is not a new name in the market. During the period in which Croma actively marketed the product, it became one of the leading hyaluronic acid brands in Europe and ranked among the top brands in its category. Its return therefore represents more than a portfolio expansion: it marks the continuation of a successful orthopaedic legacy and reconnects Croma with an important part of its history. The reintroduction of Synocrom™ also builds on Croma-Pharma’s long-standing expertise in the development and manufacturi
Murata Begins Mass Production of Seven Automotive MLCCs with World-leading Capacitance for Their Rated Voltage and Size, Supporting Stable Operation of In-vehicle Systems and Greater Design Flexibility8.4.2026 05:00:00 EEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has begun mass production of seven AEC-Q200-qualified multilayer ceramic capacitors (MLCCs) that achieve the world’s largest capacitance for a given rated voltage and size*, supporting stable operation of in-vehicle systems and greater design flexibility. Five parts in the GCM series are rated at 2.5-4 Vdc, targeting IC peripheral circuits in advanced driver assistance systems (ADAS) and autonomous driving (AD) applications. The remaining two MLCCs are rated at 25 Vdc for in-vehicle power line applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407486750/en/ [Murata Manufacturing Co., Ltd.] Seven automotive MLCCs In recent years, as ADAS and AD technologies advance, the number and performance level of systems installed in vehicles have continued to increase. As a result, demand for higher capacitance low-voltage MLCCs used around ICs has grown to e
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)7.4.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seven newly hired non-executive employees. The equity awards were granted on April 1, 2026 and consisted of options to purchase an aggregate of 117,445 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 55,875 shares. The options have an exercise price per share equal to $5.62, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted s
SLB OneSubsea and Subsea7 Sign Collaboration Agreement with PETRONAS Suriname7.4.2026 23:05:00 EEST | Press release
Global energy technology company SLB (NYSE: SLB) today announced the signing of a strategic collaboration agreement between PETRONAS Suriname E&P B.V. (“PETRONAS Suriname”), a subsidiary of PETRONAS and Subsea Integration Alliance, comprising SLB OneSubsea and Subsea7. This partnership aims to unlock resources in Suriname’s emerging frontier basin through innovative and cost-effective subsea solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331210557/en/ SLB OneSubsea has signed a strategic collaboration agreement between PETRONAS Suriname E&P B.V. (“PETRONAS Suriname”), a subsidiary of PETRONAS and Subsea Integration Alliance, comprising SLB OneSubsea and Subsea7. This partnership aims to unlock resources in Suriname’s emerging frontier basin through innovative and cost-effective subsea solutions. The agreement establishes a long-term framework for collaboration across the project lifecycle. This approach enables
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom